Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation

Simple item page
dc.contributor.authorWei, Zhigangen_US
dc.contributor.authorYang, Xiaen_US
dc.contributor.authorYe, Xinen_US
dc.date.accessioned2020-11-18T10:08:15Z
dc.date.available2020-11-18T10:08:15Z
dc.date.issued2020-09
dc.description.abstractCamrelizumab is a programmed death receptor-1 inhibitor originally developed in China for the treatment of refractory lymphoma. It has also been effective in non-small-cell lung cancer patients. However, the rechallenge of camrelizumab was not reported previously. We report the rechallenge of camrelizumab therapy in two patients previously treated with microwave ablation (MWA) and camrelizumab. Although objective responses were achieved, camrelizumab therapy was discontinued because of the development of immune-related pneumonia (IRP). Treatment with camrelizumab was reinitiated after the patients recovered from IRP. The reoccurrence of more severe IRP necessitated additional corticosteroid therapy. The rechallenge of camrelizumab in patients treated with MWA plus camrelizumab regimen and who developed IRP should be cautiousen_US
dc.identifier.affiliationsDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong Province, Chinaen_US
dc.identifier.affiliationsDepartment of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, Chinaen_US
dc.identifier.affiliationsDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, Shandong Province, Chinaen_US
dc.identifier.citationWei Zhigang, Yang Xia, Ye Xin. Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation. Journal of Cancer Research and Therapeutics. 2020 Sep; 16(5): 1191-1195en_US
dc.identifier.issn0973-1482
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213780
dc.languageenen_US
dc.publisherWolters Kluwer India Pvt. Ltd.en_US
dc.relation.issuenumber5en_US
dc.relation.volume16en_US
dc.source.urihttps://dx.doi.org//10.4103/jcrt.JCRT_798_20en_US
dc.subjectImmune-related pneumoniaen_US
dc.subjectmicrowave ablationen_US
dc.subjectnonsmall-cell lung canceren_US
dc.titleRechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablationen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcrt2020v16n5p1191.pdf
Size:
2.17 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Cancer Research and Therapeutics